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Enterovirus D68 (EV-D68) has been recognised as a 
worldwide emerging pathogen associated with severe 
respiratory symptoms since 2009. We here report 
EV-D68 detection in hospitalised patients with acute 
respiratory infection admitted to three tertiary hospi-
tals in Germany between January 2013 and December 
2014. From a total of 14,838 respiratory samples 
obtained during the study period, 246 (1.7%) tested 
enterovirus-positive and, among these, 39 (15.9%) 
were identified as EV-D68. Infection was observed in 
children and teenagers (0–19 years; n=31), the major-
ity (n=22) being under five years-old, as well as in 
adults > 50 years of age (n=8). No significant differ-
ence in prevalence was observed between the 2013 
and 2014 seasons. Phylogenetic analyses based on 
viral protein 1 (VP1) sequences showed co-circulation 
of different EV-D68 lineages in Germany. Sequence 
data encompassing the entire capsid region of the 
genome were analysed to gain information on amino 
acid changes possibly relevant for immunogenic-
ity and revealed mutations in two recently described 
pleconaril binding sites.
Introduction
Within the picornaviridae family the genus Enterovirus 
is known to include more than 120 human enterovirus 
(EV) serotypes, causing a broad range of symptoms 
mainly in children below the age of five years. The 
major clinically relevant manifestations of non-polio 
enteroviruses (NPEV) include meningitis/encephalitis 
or acute flaccid paralyses (AFP), atypical hand, foot 
and mouth-disease or myocarditis. Some serotypes 
have been identified to be predominantly associated 
with respiratory diseases. Of those, EV-D68 has, since 
its first description in 1962, been detected sporadi-
cally worldwide until 2009 [1]. Subsequently, several 
epidemic clusters of EV-D68 associated with increases 
of respiratory illnesses have been reported, [1,2]. The 
largest outbreak so far was reported in autumn 2014 
from the United States (US) with more than 1,100 
EV-D68 detections in children hospitalised with acute 
severe respiratory infections [1,3].
In Germany, surveillance of respiratory virus infections 
is conducted mainly with regards to influenza repre-
senting a vaccine preventable disease, and is based 
on sentinel surveillance systems including outpatients 
with influenza like illness (ILI) and/or acute respiratory 
infection (ARI) (AGI Influenza RKI [4]; ARE NLGA [5]). 
Furthermore, a laboratory network reporting detec-
tion of respiratory viruses in hospitalised patients was 
established in 2009 (RespVir [6]). Besides influenza, 
pathogens recorded within these systems include 
respiratory syncytial virus (RSV), human metapneu-
movirus (HMPV), parainfluenza viruses (HPIV), coro-
naviruses (HCoV), adenoviruses (HAdV), rhinoviruses 
(HRV), and EV. Since the latter viruses are not routinely 
differentiated, no valid data on EV circulation including 
EV-D68 in Germany are available.
The aim of the study was to investigate the prevalence 
of EV-D68 in Germany by analysing EV-positive respira-
tory tract samples collected from patients admitted to 
three German university hospitals in two consecutive 
years. Furthermore, nucleotide (nt) sequence analysis 
of the complete viral protein 1 (VP1) region was per-
formed for comparison of EV-D68 strains circulating 
in Germany with recent published strains from other 
countries. Complete capsid sequences from selected 
strains based on phylogenetic analysis were obtained 





Three German university laboratories provided data 
and samples collected from January 2013 through 
December 2014 to this study: the Institute of Virology 
and Immunobiology, University of Würzburg (labora-
tory 1), the Institute of Virology, University Hospital of 
Düsseldorf (laboratory 2) and the Institute of Virology, 
University of Bonn Medical Centre (laboratory 3). 
Sample collection
Respiratory samples (e.g. nasopharyngeal swabs, 
bronchial lavages) were collected from patients with 
respiratory diseases admitted to the affiliated tertiary 
hospitals. The samples were routinely screened for a 
broad panel of respiratory pathogens including EV/HRV 
and other respiratory viruses (influenza A and B, RSV, 
HMPV, HPIV 1–4, HCoV 229, NL63, HKU1, OC43, HAdV, 
parechoviruses, bocavirus) according to the individual 
laboratory protocols. All samples positive for EV or EV/
HRV were included in this study. These EV samples 
represent about one fourth of the overall number of EV 
positive samples detected in the nationwide RespVir 
surveillance [6]. 
The diagnostic procedures for the detection of respira-
tory viruses of the three university laboratories are as 
follows: laboratory 1: FTD ‘Respiratory Pathogens 21’ 
(Fast track Diagnostics, Luxembourg), laboratory 2: 
Bonzel et al., 2008 [7], laboratory 3: Dierssen et al., 
2008 [8] and Poelman et al., 2014 [9]. All methods have 
been proven to detect EV-D68 in national and interna-
tional proficiency tests.
Polymerase chain reaction amplification of 
enterovirus D68 viral protein 1 region
For highly sensitive amplification of the complete VP1 
region of EV-D68 strains directly from clinical material 
a specific one-step reverse-transcription polymerase 
chain reaction (RT-PCR) assay was established at the 
German National Reference Centre for Poliomyelitis 
and Enteroviruses (NRZ PE). Amplification was per-
formed using One-Step-RT-PCR Kit (Qiagen, Hilden, 
Germany) followed by a nested PCR using HotStarTaq-
Mastermix (Qiagen, Hilden Germany) according to the 
manufacturer’s protocol. RT-PCR and nested PCR were 
done with 600 nM of primers (Table 1). The RT-PCR was 
conducted with primers NRZ 267/268 and with the fol-
lowing temperature profile: 10 min 22 °C, 45 min 50 °C, 
15 min 95 °C for RT followed by 40 cycles (30 s 94 °C; 
30 s 55 °C; 90 s 72 °C) and final elongation for 10 min 
at 72 °C. The nested PCR was carried out with primers 
269/270 by using a touchdown protocol with 10 cycles 
(30 s 94 °C; 30 s 60 °C; 90 s 72 °C) with a decrease of 
1 °C per cycle of the initial 60 °C annealing temperature, 
followed by 30 cycles (30 s 94 °C; 30 s 50 °C; 90 s 72 °C) 
and final elongation for 10 min at 72 °C. The result-
ing product of 1,129 bp was treated with ExoSAP-IT 
(Affymetrix) before cycle sequencing with primers NRZ 
269, NRZ 270 and NRZ 271 using the BigDye 3.1 kit 
(Applied Biosystems, Weiterstadt, Germany).
Phylogenetic analysis
Sequences were assembled using Sequencher soft-
ware version 5.2.4. Alignments were performed using 
MAFFT [10] and the phylogenetic relationships among 
the strains circulating in Germany and representative 
strains taken from GenBank were estimated using 
Figure 1
Number of enterovirus (EV)-positive samples obtained by three university laboratoriesa stratified as EV-D68 and non-
EV-D68, by week, Germany, 2013–2014 (n=246)
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a The laboratories were the Institute of Virology and Immunobiology, University of Würzburg, the Institute of Virology, University Hospital of 
Düsseldorf and the Institute of Virology, University of Bonn Medical Centre.
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Figure 2
Phylogenetic analysisa of enterovirus D68 sequences (n=37) obtained by three university laboratoriesb, Germany, 2013–2014 
KP745735 GER/BY/14-1216 Germany 2014
KP114662 CA/Alberta17390 Canada 2014
KM851226 US/MO/14-18948USA 2014
KP745732 GER/BY/14-1219 Germany 2014
KP745731 GER/BY/14-1223 Germany 2014
KP745730 GER/BY/14-1226 Germany 2014
KP745770 US/NY77 USA 2014
KP745754 US/NY130 USA 2014
KP745759 US/NY275 USA 2014
KP126910 US/CA/14-6067 USA 2014
KM851225 US/MO/14-18947 USA 2014
KM881710 US/STL 2014 12 USA 2014
KM851228 US/MO/14-18950 USA 2014
KP100796 US/CA/14-6100 USA 2014
KP745755 US/NY153 USA 2014
KP100793 US/CO/14-94 USA 2014
KP126911 US/CO/14-94 USA 2014
KM851227 US/MO/14-18949 USA 2014
KM892502 US/CA/AFP/v14T04344 California 2014
 KP100792 US/CA/14-6092 USA 2014
KP322752 US/CA/14-6089 USA 2014
KP745763 US/NY314 USA 2014
KP126908 US/CA/14-R2 USA 2014
KP100794 US/CO/14-60 USA 2014
KP126912 US/CO/14-86 USA 2014
KP114663 CA/Alberta4693 Canada 2014
KP153539 IT//23987/14 Italy 2014
KP153541 IT/25571/14 Italy 2014
KP153546 IT/25861/14 Italy 2014
KP153540 IT/25185/14 Italy 2014
KP153542 IT//25663/14 Italy 2014
KP153545 IT/25702/14 Italy 2014
KP153544 IT/25700/14 Italy 2014
KP153543 IT/25686/14 Italy 2014
KR066457 GER/NW/15-88 Germany 2013
KM892498 US/CA/AFP/v12T04950 California 2013
KM892499 US/CA/AFP/v12T00346 California 2013
KP114664 CA/Alberta2985 Canada 2014
KP240936 CHN/Beijing-R0132 China 2014
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B1
KR066451 GER/BY/14-1316 Germany 2013
KP745739 GER/NW/14-1057 Germany 2014
KM851229 US/KY/14-18951 USA 2014
KM851230 US/IL/14-18952 USA 2014
KP114665 CA/Alberta17789 Canada 2014
KR066456 GER/NW/15-58 Germany 2014
KR066448 GER/NW/14-1035 Germany 2013
KR066450 GER/NW/14-1047 Germany 2014
KR066447 GER/NW/14-1037 Germany 2013
KR066449 GER/NW/15-114 Germany 2013
KR066452 GER/NW/15-113 Germany 2013
KR066446 GER/BY/14-1197 Germany 2014
KR066453 GER/BY/14-1317 Germany 2013
KR066455 GER/NW/15-34 Germany 2013
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KR066445 GER/BY/14-1189 Germany 2014
KP745768 US/ NY73 USA 2014
KR066438 GER/NW/15-118 Germany 2013
KP745736 GER/BY/14-1214 Germany 2014
KR066454 GER/NW/15-36 Germany 2013
KR066440 GER/NW/14-1273 Germany 2013
KR066444 GER/BY/114-1318 Germany 2013
B2
AB667886 JP/Yamagata/1991 Japan 2005
AB601882 JP/10-290 Japan 2010
AB601884 JP/10-396 Japan 2010
AB667895 JP/Yamagata/1703 Japan 2007
AB601885 JP/10-404 Japan 2010
JX101786 US/ARI192 USA 2009
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EF107098 FR/37-99 France 1999
X070222 NZ/2010-541 New Zealand 2010
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KM361525 TH/CU70 Thailand 2011
JX101788 SN/SEN30 Senegal 2010
KM892500 US/CA/RESP/10-786 California 2013
JX101790 GM/GA420 Gambia 2008
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A1
AB667899 JP/Yamagata/1737 Japan 2008
KF726085 CHN/BCH895A China 2008
KP745729 GER/BY/14-1227 Germany 2014
KKM851231 US/KY/14-18953 USA 2014
KR066461 GER/BY/14-1020 Germany 2014
KR066458 GER/NW/15-68 Germany 2014
KR066459 GER/BY/14-1311 Germany 2013
KR066460 GER/NW/14-1275 Germany 2014
KP745742 GER/BY/14-1025 Germany 2014
KP153538 IT/23341/14 Italy 2014
KP745741 GER/BY/14-1026 Germany 2014
A2
AY426489 US/MN89 USA 1989
AY426490 US/NY93 USA 1993
AY426488 US/CA62-3 USA 1962
AY426531 Fermon










































The phylogenetic analysis is based on the complete viral protein 1 region. Bootstrap values are shown at the nodes. The scale bar indicates the number of nucleotide (nt) 
substitutions per site.
a The complete VP1 region nt sequence corresponded to bases 2,389 –3,315 of EV-D68 prototype strain Fermon (GenBank accession number: AY426531).
b The laboratories were the Institute of Virology and Immunobiology, University of Würzburg, the Institute of Virology, University Hospital of Düsseldorf and the Institute of 
Virology, University of Bonn Medical Centre.
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the maximum likelihood (ML) method based on the 
Tamura–Nei model conducted with molecular evolu-
tionary genetics analysis (MEGA6) using a bootstrap 
procedure with 1,000 replicates [11].
Molecular typing of non-enterovirus D68 
enteroviruses
Molecular typing of non-EV-D68 enteroviruses was car-
ried out by sequencing of the VP1 region using pub-
lished PCR systems with slightly modified conditions 
due to use of the Qiagen One Step RT-PCR kit instead 
of Invitrogen Superscript II and III as described in ref-
erences [12,13]. Details of methodology are available 
upon request. For those samples remaining VP1 PCR 
negative, sequencing of partial 5’non-coding region 
(5’NCR) [14] allowed assignment to enterovirus group 
A–D. Samples with no clear basic local alignment 
search tool (BLAST) result were classified as NPEV.
Analysis of immunogenic sites in the capsid 
proteins of enterovirus D68
To provide sequence data for further understand-
ing of possible changes in the immunogenic sites of 
the capsid, 23 strains representing members of all 
three current subclades (A2, B1, B2) were selected for 
sequencing of the entire capsid (P1) genomic region 
encoding all four capsid proteins as well as adjacent 
5’NCR region. Amplification of the VP4/VP2/VP3 region 
of the genome from clinical material was performed 
with primers listed in Table 1 using the following 
cycling protocol: 45 min 50 °C, 15 min 95 °C followed by 
25 cycles (30 s 94 °C; 30 s 55 °C; 90 s 72 °C) and final 
elongation for 10 min at 72 °C. Nested PCR was carried 
out 15 min at 95 °C followed by 25 cycles (30 s 94 °C; 
30 s 55 °C; 30 s 72 °C) and final elongation for 10 min 
at 72 °C. PCR products were directly sequenced after 
EXOSAP-IT treatment with primers used for nested 
PCR. Amplification and sequencing of partial 5’NCR 
was done as described recently [14].
Results
Enterovirus D68 detection
From January 2013 to the end of December 2014, 14,838 
respiratory samples from patients admitted to three 
tertiary university hospitals were analysed, with 246 
(1.7%) being EV- positive. EV-positive samples were 
retrospectively typed with molecular methods result-
ing in a total of 39 EV-D68 detections with 17 (0.2%) 
detections in 2013 and 22 (0.3%) detections in 2014 
(Table 2). 
When analysed in more detail, variations in EV-D68 
prevalence among patients admitted to each of the 
three hospitals were noticed. While in one hospital a 
moderate raise in EV-D68 infections among total sam-
ples analysed was observed in 2014 compared with 
2013 (0.2% in 2013 vs 0.6% in 2014), another hospital 
showed a higher EV-D68 rate in 2013 (0.6% in 2013 vs 
0.1% in 2014).
Weekly distribution of EV-D68 positive samples, 
as shown in Figure 1, peaked in late summer and 
autumn months (September–November). This was 
also reflected by the EV-D68-positivity rates among 
EV-positive samples, which in calendar weeks 36 to 48 
corresponding to September to November (last column, 
Table 2) ranged from 23.8 to 54.5%. Regarding the indi-
vidual hospitals, EV-D68 was detected nearly consist-
ently among EVs during weeks 36 to 48 in hospital 
1 and 2 (54.5% in 2013 vs 50.0% in 2014; and 27.3% 
in 2013 vs 23.8% in 2014). Hospital 3 showed higher 
EV-D68 rate in 2013 (45.5%) than in 2014 (25.0%), how-
ever, some caution is needed concerning this hospital 
because of the relatively small number of EV-D68- pos-
itive samples which might be biased by the overall low 
number of EV detections. On average, no substantial 
differences in EV-D68 rates could be found between 
2013 and 2014 suggesting two regular seasons.
The 39 EV-D68 samples detected over the whole study 
period were from young children aged 0–9 years 
(n = 28), teenagers aged 10–19 years (n = 3) and adults 
aged > 50 years (n = 8). Within the group of young chil-
dren, the majority of EV-D68 patients was under the 
age of five years (n = 22). The male/female ratio for 
EV-D68-positive patients was 1.4:1 (m = 23, f = 16). 
Co-infection with other viruses was observed in two 
EV-D68-positive samples (Cox A10, n=1; HCoV OC43, 
n=1). Specified clinical details were not accessible for 
all EV-D68 patients. For patients where data were avail-
able (n = 15), pneumonia (n = 6) or obstructive bronchi-
tis (n = 6) were most commonly reported.
Amplification and phylogenetic analysis based 
on viral protein 1 region
Amplification of the complete VP1 sequence was 
achieved for 37 of 39 EV-D68 samples. For phyloge-
netic analysis complete VP1 sequences of EV-D68 
strains available in GenBank were used. The ML tree 
confirmed the previously observed divergence of 
EV-D68 strains circulating since 2005 into three major 
subgroups A, B, and C (Figure 2) [15]. Furthermore, 
as recently described, subgroups A and B segregated 
in two subclades [16]. Among the 37 EV-D68 strains, 
seven belonged to clade A2 and 30 belonged to clade B 
(B1: n = 5, B2: n = 25). All sequences were deposited in 
GenBank under accession numbers KP745729–43 and 
KR066438–61.
Amplification and sequencing of partial VP1 region 
from non-EV-D68 viruses revealed serotypes from 
enterovirus species EV-A (n = 87) and EV-B (n = 68). 
Typing results are shown in more detail in Table 3. 
Samples remaining negative in VP1 amplification were 
categorised as EV-A (n = 3), EV-B (n = 6), and EV-C (n = 1) 
by 5´NCR sequencing. Fifteen samples were identified 
as rhinovirus (HRV-A: n = 8, HRV-C: n = 7). Twenty-nine 
samples gave no clear BLAST result and were classified 

















































































































Analysis of complete capsid region (P1) 
amino acid- and partial 5’non-coding region 
sequences
Twenty-three EV-D68 sequences of strains belonging 
to subclades A2, B1, and B2 from this study were com-
pared with 40 sequences available through GenBank. 
There were only few amino acids exclusively defining 
a single clade, however clade A was characterised by 
E143 and V291 in VP2, N525 and V533 in VP3 and a dele-
tion of N692 in VP1. Strains assigned to subclade A2 
carried an arginine and lysine insertion at position 859 
of VP1. No differences between strains circulating in 
2014 and strains circulating before 2014 were observed 
with regard to the defined loop structures of the capsid 
proteins VP1, VP2, and VP3 representing neutralising 
immunogenic sites (VP2 EF loop, VP3 BC loop, VP1 BC 
loop and DE loop; alignment available upon request). 
Notably, two amino acid positions that have been 
reported to interact with the antiviral pleconaril dif-
fered in strains assigned to subclade B1 compared with 
the other EV-D68 strains: M341A(VP3) and V746I(VP1) 
[17]. Whether or not these changes influence pleconaril 
efficacy requires experimental confirmation.
Within the 3’ end of the 5’NCR, all strains included in 
the comparison showed a 23 or 24 nt deletion (681–
703/704 compared with prototype strain Fermon). In 
addition, all B and C strains carried a 12 or 13 nt dele-
tion (713–724/725 compared with Fermon), except 
strain KM892501 (Figure 3).
Discussion
In this study we provide epidemiological and phyloge-
netic information on EV-D68 in hospitalised patients 
admitted with respiratory diseases to three tertiary hos-
pitals in Germany from January 2013 through December 
2014. During this period, EV-D68 circulation appeared 
to have a seasonal pattern, with an increase in num-
bers of patient samples testing positive for this virus 
from the beginning of the autumn until the early winter 
months. The apparent seasonality was also reflected in 
the EV-D68 positivity rates among enterovirus-positive 
samples from September to November (calendar week 
36–48), which ranged between 23.8% and 54.5%, 
compared to between 8.3% and 23.4% annually. 
Overall EV-D68 infections could be detected in chil-
dren and teenagers, with most detections in those 
under five years-old. Adults over 50 years of age were 
also affected. The male/female ratio of 1.4:1 among all 
respiratory isolates indicated a male predominance, 
which has also been previously described for enterovi-
rus-infected patients [18].
Among the total annual numbers of analysed respira-
tory samples, EV-D68 was detected at a rate of 0.2% 
(2013) and 0.3% (2014). The similar rates between the 
two years suggest that each year was characterised by 
a regular season. In support of this, similar prevalences 
have been reported for hospitalised patients [19-21] as 
well as outpatients [18,22] from several studies world-
wide in non-epidemic years. In contrast, for years with 
described increased EV-D68 activity, an overall annual 
EV-D68 detection rate of > 1% has been observed in 
hospitalised patients [20,23,24] as well as outpatients 
[22,25].
Table 1
Primers used for amplification and sequencing of the complete capsid (P1) region of enterovirus D68 
Target region and primer Sequence 5'–3' Orientation Locationa
VP1
NRZ 267 ATG YTA GST ACW CAT RTB GTB TGG GAY TT Sense 2,125–2,153
NRZ 268 ATC CAY TGR ATM CCW GGG CCY TCR AAR C Antisense 3,557–3,530
NRZ 269 AAT GCY AAY GTT GGY TAY GTY ACH TGT T Sense 2,239–2,266
NRZ 270 AAG AYC CYA CAA ARA CYC CHC CRW ARC CKG G Antisense 3,358–3,327
NRZ 271 CAA GCA ATG TTY GTA CCH ACT GG Sense 2,854–2,876
VP2/4
NRZ 272 GTG GTC CAG GCT GCG TTG GCG Sense 350–370
NRZ 273 TTR AAC TCA CAA CAC ATT GGA GCR ATT G Antisense 1,658–1,631
NRZ 274 ATG AAC AAG GTG TGA AGA GTC TAT TGA GC Sense 405–433
NRZ 275 ACT GGT ATT ATT GCT AGY GTC CAC TG Antisense 1,580–1,555
VP3
NRZ 276 TGA CAT CAT GAA AGG TGA AGA AGG AGG Sense 1,371–1,397
NRZ 277 GTG CGA GTT TGT ATG GCT TCY TCT GG Antisense 2,564–2,539
NRZ 278 GTT CTT CCC TGG ATG AAT GCY GCT CC Sense 1,504–1,529
NRZ 279 CTC TCR ATY TGR TAG GCT GCC TCT G Antisense 2,432–2,408
VP: viral protein.
a Nucleotide locations are relative to the genome of EV-D68 prototype strain Fermon (GenBank accession number: AY426531).
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A more detailed data analysis revealed variation in 
EV-D68 prevalence among patients admitted to each 
of the three hospitals in our study between the years, 
suggesting a broad range in EV-D68 positivity rates 
from one season to another. The annual rates of EV-D68 
positivity among all respiratory samples for each hos-
pital during the study period remained however <1%. 
Worldwide reports on the detection of EV-D68 in 
patients with respiratory diseases increased rapidly 
during the last few years especially during the 2008 
to 2010 period [2]. The observation of an upsurge in 
hospitalised patients due to EV-D68 infection in the US 
and Canada in 2014 [1,3,26] resulted in the recognition 
of EV-D68 as an (re)emerging pathogen. In response to 
this, the European Society for Clinical Virology (ESCV) 
launched a study in collaboration with the European 
Centre for Disease Prevention and Control (ECDC) to 
collect information on EV-D68 infections in paediatric 
patients in September/October 2014 in Europe [16]. 
We contributed to this study and therefore samples 
collected between September 2014 and November 
2014 reported here were also included in that study. 
However, no epidemiological data on EV-D68 in 
Germany covering a period as extended as this current 
study have been described so far. The only data avail-
able to date came from an EV-D68-specific screening of 
samples collected within the German ILI/ARI outpatient 
study during the August to October 2014 period, result-
ing in identification of 25 EV-D68-positive samples 
among 325 samples (7.7%) screened [27].
Coinciding with the upsurge of severe acute respira-
tory diseases in the US and Canada in 2014, a cluster 
of 12 paediatric patients with AFP following respiratory 
illness was reported from Colorado [28,29]. Among 11 
of these children, five (45%) tested EV-D68 positive in 
respiratory specimens [28,29]. A further investigation 
of AFP cases reported nationwide in the US during the 
same period (August through October) found 88 cases 
of AFP in 32 States, revealing a similar EV-D68 positive 
rate [30]. In contrast, no development of central nerv-
ous system (CNS) complications was reported in the 
patients from this study. Furthermore, in the context of 
the Global Polio Eradication Initiative programme, the 
German enterovirus surveillance [31] reported no sig-
nificant increase of AFP cases in 2013 and 2014 com-
pared to the 2006 to 2014 average in Germany (Katrin 
Neubauer, personal communication 15 May 2015). 
As part of the EVSurv, laboratory diagnostics focus 
mainly on stool samples from patients with symp-
toms of aseptic meningitis/encephalitis and/or AFP to 
exclude polioviruses. Stool samples are nevertheless 
not suitable for EV-D68 detection, due to the biological 
properties of this virus [32,33]. In spite of this, among 
24,246 specimens tested for enteroviruses between 
2006 and 2014 within the EVSurv, three stool samples 
from paediatric patients with signs of aseptic menin-
gitis were reported as EV-D68-positive (2 in 2010, 1 in 
2013). These most probably resulted from spill-over 
from the respiratory tract, but nevertheless suggest 
circulation of EV-D68 in Germany before 2013 and pre-
sumably possible association with CNS disorders.
As different EV-D68 clades are evolving over time [15], 
the increased detection of EV-D68 in the recent dec-
ade may have been due to changes in antigenicity [34]. 
Comparison of the complete capsid sequences of 23 
strains isolated in 2013 and 2014 in Germany with ref-
erence strains obtained from GenBank did not reveal 
any amino acid residues in antigenic sites that were 
unique to the 2013 or 2014 strains. 
Furthermore, all German strains described here 
showed clade specific deletions within the 3’ end of 
5’NCR as reviewed in Imamura and Oshitani in 2014 
[2]. All clade A strains identified in this study displayed 
Table 2
Overview of respiratory samples analysed and enterovirus (EV) and EV-D68 detection rates by three university 















Number of EV-D68/EV 
positives (%) in  
calendar week 36 - 48
1 
2013 3,526 46 (1.3) 6 (0.2) 6/46 (13.0) 6/11 (54.5)
2014 2,696 64 (2.4) 15 (0.6) 15/64 (23.4) 12/24 (50.0)
2 
2013 3,351 55 (1.6) 6 (0.2) 6/55 (10.9) 3/11 (27.3)
2014 3,753 44 (1.2) 6 (0.2) 6/44 (13.6) 5/21 (23.8)
3 
2013 813 25 (3.1) 5 (0.6) 5/25 (20) 5/11 (45.5)
2014 699 12 (1.7) 1 (0.1) 1/12 (8.3) 1/4 (25.0)
Total 2013 7,690 126 (1.6) 17 (0.2) 17/126 (13.5) 14/33 (42.4)
Total 2014 7,148 120 (1.7) 22 (0.3) 22/120 (18.3) 18/49 (36.7)
Total 2013–2014 14,838 246 (1.7) 39 (0.3) 39/246 (15.8) 32/82 (39.0)
a The laboratories were the Institute of Virology and Immunobiology, University of Würzburg, the Institute of Virology, University Hospital of 
Düsseldorf and the Institute of Virology, University of Bonn Medical Centre.
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the previously described deletion within the DE loop 
in VP1 [21]. Interestingly, all German strains assigned 
to subclade A2 were identified in seven of eight adult 
patients. Those strains carried a subclade A2 specific 
insertion of two amino acids (arginine and lysine) at 
the very end of the C-terminus of VP1. So far, no func-
tion has been assigned to this region. Comparison with 
prototype sequences of all other known enterovirus 
serotypes revealed a highly diverse C-terminus of VP1 
downstream from a conserved proline-rich region (data 
not shown, available upon request). Furthermore, we 
recognised two amino acid exchanges in subclade B1 
strains (M341A in VP3 and V746I in VP1) at positions 
that have been described to interact with pleconaril 
[17] (data not shown, available upon request).
In summary, no significant changes in the EV-D68 
prevalence in patients admitted to three German ter-
tiary hospitals could be observed in 2014 compared 
with 2013. On the basis of amino acid sequences of 
the capsid proteins no unique changes in 2014 strains 
compared with 2013 strains or clade specific differ-
ences were found. However, the insertion of two amino 
acids at the C-terminus of VP1 of subclade A2 strains, 
combined with their occurrence in adults, warrants 
further experimental investigation regarding neutrali-
sation properties of antibodies directed against (i) 
the strains not containing this insertion versus (ii) the 
strains containing the insertion. Furthermore, continu-
ous molecular surveillance of enteroviruses in respira-
tory samples using defined criteria is a necessity to be 
able to interpret potential epidemiological and clini-
cal situations like those recently reported from North 
America and Canada.
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